Table 1. Comparison of Characteristics in Those who are Alive vs. Those who Died/Lost to Follow up.
| Characteristic | Total (%) | Alive (%) | Death/LFU (%) | P* |
| n = 367 | n = 323 | n = 44 | ||
| Cryptococcal Antigen Positive | 31 (9) | 28 (9) | 3 (7) | 0.68 |
| Demographics | ||||
| Mean Age in years (IQR) | 36.7 (30–41) | 36.9 | 35.1 | 0.20 |
| Male | 163 (45) | 141 (44) | 22 (50) | 0.44 |
| BMI <18.5 kg/m2 | 97 (26) | 81 (25) | 16 (36) | 0.11 |
| Site 1 vs. 2 | 262 (71) | 229 (71) | 33 (75) | 0.57 |
| ART Use | ||||
| ART at Baseline | 270 (74) | 245 (76) | 25 (57) | 0.006 |
| ART at Follow-Up (n = 351) | 328 (94) | 314 (98) | 14 (48) | <.0001 |
| Median time on ART in patients on ART at Follow-Up# (months) [IQR] | 30.5 (13–64) | 32 (14–66) | 7.7 (5–13) | <.01 |
| CD4 Count Status | ||||
| CD4<100 vs. 100–200 at Baseline | 117 (32) | 93 (29) | 24 (55) | 0.001 |
| Mean CD4 Increase at Follow-Up (n = 351) [IQR] | 75 (1–122) | 79.5 | 36.1 | 0.02 |
| Opportunistic Infections | ||||
| Treated for TB at Baseline or during follow-up | 43 (12) | 38 (12) | 5 (11) | 0.94 |
| Treated for Pneumonia at baseline or during follow-up | 42 (11) | 37 (12) | 5 (11) | 0.99 |
| Herpes Zoster at baseline or during follow-up | 35 (10) | 30 (9) | 5 (11) | 0.66 |
CRAG, serum cryptococcal antigen; BMI, body mass index; ART, antiretroviral therapy; OI, opportunistic infection; TB, tuberculosis; URI, upper respiratory infection acid. Other risk factors with not enough statistical numbers to analyze: alcohol use (11), Illicit Drug Use (7), Diabetes Mellitus (1), Hepatitis (3), Malignancy (8). *Univariate analysis; #Missing data for 22 patients.